Alder Announces Presentations at Annual Meeting of the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention

BOTHELL, Wash., June 02, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine, and preclinical data from a case study of  ALD403 and other CGRP-antibodies will be presented at the upcoming 58th Annual Scientific Meeting of the American Headache Society on June 9-12, 2016 in San Diego.

  • Oral presentation by Jeffrey T.L. Smith, M.D., FRCP, Senior Vice President, Translational Medicine at Alder: “Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine”

Oral Session: Scientific Paper Presentations - Session 2 Presenter: Dr. Jeffrey Smith Date: Saturday, June 11 Time: 11 am PDT Location: Marina Ballroom, D-F

  • Poster presentation: “A Characterization of the CGRP-Antibody Interactions of Therapeutic Antibodies Effective in Preventing Migraine: a Comparative Pre-Clinical Case Study of ALD403 and Other CGRP Antibodies”

Poster #: PS74LB Date: Friday, June 10 Poster Q & A Session: 1:15 pm – 2:30 pm PDT Location: San Diego Ballroom

  • Poster presentation: “A Multiple Dose, Placebo-Controlled, Randomized Phase I Clinical Trial of ALD403, a Humanized anti-Calcitonin Gene-Related Peptide Monoclonal Antibody, Administered Once Every 3-Months via IV, SC, or IM – Pharmacokinetic and Pharmacodynamic Results”

Poster #: PS79LB Date: Saturday, June 11 Poster Q & A Session: 12:30 pm – 2:00 pm PDT Location: San Diego Ballroom

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder's lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder's second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of congenital adrenal hyperplasia and Cushing's disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies, and an IND submission is planned for 2016. Additionally, clazakizumab, a monoclonal antibody therapeutic candidate discovered by Alder designed to block interleukin-6, is licensed to Vitaeris, Inc. For more information, please visit  http://www.alderbio.com . 

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of ALD403 and ALD1613; and future regulatory filings.  Words such as "potential," "intended," "planned," or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of ALD403 and ALD1613 to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of ALD403 and ALD1613; risks and uncertainties related to regulatory review and approval processes and Alder's compliance with applicable legal and regulatory requirements; and other factors discussed under the caption "Risk Factors" in Alder's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016, which was filed with the Securities and Exchange Commission (SEC) on April 28, 2016, and is available on the SEC's website at www.sec.gov.  Additional information will also be set forth in Alder's other reports and filings it will make with the SEC from time to time.  The forward-looking statements made in this press release speak only as of the date of this press release.  Alder expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Alder's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

 

Media Contacts: David Schull or Lena Evans Russo Partners, LLC (212) 845-4271 (212) 845-4262 david.schull@russopartnersllc.com lena.evans@russopartnersllc.com Investor Relations Contact: David Walsey Alder Biopharmaceuticals (425) 408-8032 ir@alderbio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 53

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 161

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading

Top 5 Most Recently Viewed Articles

Leech Tishman Expands Healthcare Practice with Nelson Hardiman

Updated Category News Views 79

Leech Tishman Expands Its Healthcare Practice with Major Addition Leech Tishman is making a significant move in its growth strategy by merging with the respected healthcare firm, Nelson Hardiman. This collaboration is set to enhance Leech Tishman’s footprint in the healthcare sector, especially in the Southern California region, as they prepare to operate under the name...

Continue Reading
Schouw & Co. Announces Success in Share Buy-Back Program

Updated Category News Views 105

Schouw & Co. Share Buy-Back Program Overview Schouw & Co., a notable player in the business landscape, has embarked on an impactful share buy-back program that began recently. This strategic move allows the company to purchase shares worth up to DKK 50 million over a designated time frame, from January 2 to March 31. Such initiatives reflect the company's commitment to...

Continue Reading
Earnings Season Set to Shape Market Dynamics Amid Tariffs

Updated Category News Views 150

Understanding Market Sentiment During Earnings Season The upcoming earnings season presents an opportunity for Wall Street to shift its attention from external geopolitical factors to the internal dynamics of corporate performance. As companies prepare to unveil their second-quarter earnings reports, a closer look at how tariffs could influence consumer spending and,...

Continue Reading
Josh Ruben Joins the Board of PetVivo Holdings to Drive Growth

Updated Category News Views 316

Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) has announced the addition of Josh Ruben to its Board of Directors. This news comes from the company's efforts to further establish itself within the biomedical device sector aimed at improving the quality of life for companion animals. Transformational Leadership...

Continue Reading
Innovative Portable Solar and Wind Generator Concept Unveiled

Updated Category News Views 120

Your Sustainable Charging Solution We live in a time where sustainable energy solutions are becoming more paramount, and the invention of a portable solar and wind-powered generator meets that demand head-on. The concept builds on the idea that everyone deserves access to clean energy alternatives, especially for charging electronic devices. The Vision Behind the...

Continue Reading